Showing 2551-2560 of 5909 results for "".
- Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansionhttps://modernod.com/news/euclid-systems-names-key-leadership-hires-and-announces-major-facility-expansion/2480465/Euclid Systems announced two additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-gene
- Heidelberg Engineering Receives European Acceptance for Spectralis Shift Technology Under New Medical Device Regulationhttps://modernod.com/news/heidelberg-engineering-receives-european-acceptance-for-spectralis-shift-technology-under-new-medical-device-regulation/2480442/Heidelberg Engineering announced the launch of the Spectralis platform with shift technology, which is designed to create synergies that significantly increase efficiency in both OCT and OCTA, and deliver images with more detail. Shift enables clinicians to switch between OCT scan
- CORD LLC Completes One-Year Follow-Up on Subjects From the Model SC9 Intraocular Lens FDA Clinical Trialhttps://modernod.com/news/cord-llc-completes-one-year-follow-up-on-subjects-from-the-model-sc9-intraocular-lens-fda-clinical-trial/2480435/Cumming Ophthalmic Research and Development
- Study Shows Contact Lenses Advantages with Mask Wearhttps://modernod.com/news/study-shows-contact-lenses-advantages-with-mask-wear/2480420/A new study establishes that contact lens wear offers an option for a better vision correction experience than spectacles when paired with face masks, and doing so likely improves adherence to mask use. Conducted by Eurolens Research at the University of Manchester, it is the first work to compar
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategyhttps://modernod.com/news/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy/2480411/Kiora Pharmaceuticals is the new name of EyeGate Pharmaceuticals. The new brand reflects the company’s aim to not only treat common eye conditions, but to develop a small molecule therapy for retinitis pigmentosa. Kiora will trade on the Nasdaq
- CooperVision Introduces MyDay Daily Disposable Multifocal Contact Lenses in UShttps://modernod.com/news/coopervision-introduces-myday-daily-disposable-multifocal-contact-lenses-in-us/2480403/At the 2021 American Academy of Optometry Meeting, CooperVision introduced MyDay daily disposable multifocal contact lenses, expanding its premium silicone hydrogel 1 day family in the United States. The new lenses are the first to feature the CooperVision
- Tarsus Pharmaceuticals Presents Data from Two Studies on the Prevalence and Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/Tarsus Pharmaceuticals presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for ov
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injuryhttps://modernod.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/IACTA Pharmaceuticals announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain utilizing
- Tilak Healthcare Raises €7m to Deploy Its Remote Vision Monitoring Platformhttps://modernod.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/Tilak Healthcare, a developer of mobile games with medical modules to monitor patients with chronic ophthalmological conditions, has announced a €7 million fundraising round managed by Elaia, with the participation of Swen Capital Partners, Matmut Innovation, and co-founder